Abatacept is a disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease. Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).
- Mechanism
- Curator reviewed
Abatacept is a selective costimulation modulator - like CTLA-4, the drug has shown to inhibit T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Blockade of this interaction has been shown to inhibit the delivery of the second co-stimulatory signal required for optimal activation of T-cells. This results in the inhibition of autoimmune T-Cell activation that has been implcated in the pathogenesis of rheumatoid arthritis.
- Primary indication
- Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and in patients ≥2 years of age for the treatment of active psoriatic arthritis.Curator reviewed · 7 structured indications
- Formula / weight
- C3498H5458N922O1090S32 · 92300.0 Da (with glycosylation)
- First approval
- Canada, 2006 · United States, 2009 · European Union, 2021
- Also known as
- Abatacept recombinant
- Code names
- BMS-188667 · CTLA4-IGG4M · RG-1046 · RG-2077
- Brand names
Resolves to
What you can answer from here — as of September 12, 2026
Which drugs share a target with Abatacept, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account